<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04858659</url>
  </required_header>
  <id_info>
    <org_study_id>PK101_P301</org_study_id>
    <nct_id>NCT04858659</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study to Assess the Efficacy and Safety of PK101 in Patients With Knee Osteoarthritis</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Active-controlled, Parallel-designed, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of PK101 Compared With PK101-002 in Patients With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PMG Pharm Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PMG Pharm Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and the safety of PK101 in patients with&#xD;
      knee osteoarthritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this study is to evaluate the efficacy of PK101 compared with&#xD;
      PK101-002 at Week 8 in osteoarthritis. Also evaluates the safety of PK101.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2021</start_date>
  <completion_date type="Anticipated">March 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change during activity in 100mm Pain VAS</measure>
    <time_frame>baseline through week 8</time_frame>
    <description>Visual Analogue Scale, 0 mm no pain, 100 mm worst pain ever</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change during activity in 100mm Pain VAS</measure>
    <time_frame>baseline through week 4</time_frame>
    <description>Visual Analogue Scale, 0 mm no pain, 100 mm worst pain ever</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change at rest in 100mm Pain VAS</measure>
    <time_frame>baseline through week 4, 8</time_frame>
    <description>Visual Analogue Scale, 0 mm no pain, 100 mm worst pain ever</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in WOMAC(Western Ontario and McMaster Universities Osteoarthritis Index using the Visual Analogue Scale, Version 3.1) sub scale &amp; total score</measure>
    <time_frame>baseline through week 4, 8</time_frame>
    <description>Assessment of pain, stiffness and physical function. Score range 0-500 mm for Pain, 0-200 mm for Stiffness, and 0-1700 mm for Physical Function. Higher scores indicate worse pain, stiffness, and functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PGA</measure>
    <time_frame>baseline through week 8</time_frame>
    <description>PGA for disease severity (Patient's Global Assessment, 1=Very good, 2=Good, 3=Fair, 4=Poor, 5=Very Poor)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SF-36 sub scale &amp; PCS, MCS as measured by Health Survey(Short Form, SF-36 v2, Physical Component Summary, Mental Component Summary)</measure>
    <time_frame>baseline through week 8</time_frame>
    <description>The SF-36 v2 is a 36-item, patient-reported survey of patient's health, consisting of 2 components(the PCS and the MCS) included 8 subscales.&#xD;
Patients rated their QoL using a 2-6 point Likert Scale. Score is converting the original score to 0~100 points.&#xD;
The lower score means poor health status, and the higher score, the better.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">354</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>PK101 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PK101-002 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PK101</intervention_name>
    <description>1 tablet at each time, 2 times a day</description>
    <arm_group_label>PK101 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PK101-002</intervention_name>
    <description>1 tablet at each time, 2 times a day</description>
    <arm_group_label>PK101-002 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PK101 placebo</intervention_name>
    <description>1 tablet at each time, 2 times a day</description>
    <arm_group_label>PK101-002 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PK101-002 placebo</intervention_name>
    <description>1 tablet at each time, 2 times a day</description>
    <arm_group_label>PK101 group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥40 and of age&#xD;
&#xD;
          -  Patients who meets the American College Rheumatology (ACR) criteria and has lasted for&#xD;
             at least three months after diagnosis of one-sided or bilateral knee osteoarthritis.&#xD;
&#xD;
          -  Radiographic evidence of grade 1 ~ 3 osteoarthritis based on the Kellgren &amp; Lawrence&#xD;
             radiographic entry criteria at visit 1&#xD;
&#xD;
          -  Score of 100mm pain VAS ≤ 80mm at visit 1&#xD;
&#xD;
          -  Written consent form voluntarily&#xD;
&#xD;
          -  Score of 100mm pain VAS ≥ 40mm at visit 3&#xD;
&#xD;
          -  Patients with an individual medication compliance of 70% or more of the IP&#xD;
             administered during the Run-in period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who has a history of hypersensitivity to components of IP, NSAIDs including&#xD;
             COX-2 inhibitors, a history of hypersensitivity to aspirin, or allergic reactions to&#xD;
             sulfonamides&#xD;
&#xD;
          -  Patients with inflammatory, infectious, metabolic, septic arthritis or rheumatoid&#xD;
             arthritis other than osteoarthritis&#xD;
&#xD;
          -  Patients with a condition that can affect the joints&#xD;
&#xD;
          -  Patients who have undergone arthroscopic surgery within 1 year , knee joint surgery&#xD;
             within 5 years, synoviorthesis within 3 months prior to visit 1 to the target knee, or&#xD;
             who have planned surgery during the trial period&#xD;
&#xD;
          -  Patients who have used corticosteroids as follows:&#xD;
&#xD;
               -  Inj. of corticosteroid, including intraarticular administration, into the target&#xD;
                  knee within 3 months prior to visit 1&#xD;
&#xD;
               -  Oral corticosteroid administration within 1 month prior to visit 1&#xD;
&#xD;
          -  Patients who have intraarticular injected hyaluronic acid or cell therapy products,&#xD;
             gene therapy products, etc. for the treatment of osteoarthritis within 3 months prior&#xD;
             to visit 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jeonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wan-Hee Yoo</last_name>
      <phone>82-63-250-2377</phone>
      <email>ywhim@chonbuk.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 5, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

